Longitudinal Antibody Responses to *Vibrio cholerae*: A Systematic Review

Aparna Mangadu[1], Christy Clutter[1], Kenadee Jacobson[1], Tatum Heiner[1], Md. Saruar Bhuiyan [1], Shubhanshi Trivedi[1], Benjamin Brintz[1], Andrew S. Azman[2-4], Benjamin F. Arnold[5], Daniel T. Leung[1]

[1] Division of Infectious Diseases, Department of Internal Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA
[2] Division of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
[3] Institute of Global Health, University of Geneva, Geneva, Switzerland
[4] Division of Tropical and Humanitarian Medicine and Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.
[5] Francis I. Proctor Foundation and Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA

Abstract

Cholera is a critical global health threat with significant morbidity and mortality, particularly in low- and middle-income countries and populations without access to safe water and sanitation. Clinical surveillance is typically based on non-specific and microbiological diagnostics that are only moderately sensitive. Therefore, identifying cases and understanding the true burden is difficult. Measurements of antibodies can help inform interpretation of cross-sectional sero-epidemiological studies assessing infection burden. We conducted a systematic review to identify literature from 1980 to 2025 containing longitudinal antibody kinetics in humans following exposure to *Vibrio cholerae O1/O139* and associated vaccines. 51 studies representing adults (18-65 years) and pediatric (2 months-17 years) populations from 5 high-income (21 studies), 3 upper-middle-income (5 studies), 5 lower-middle-income (24 studies), and 1 low-income (1 study) countries were included. 16 studies followed natural cholera infection, 38 involved vaccination, and 6 were human challenge models, with some overlap. Antibody responses following natural infection were significantly higher than those induced by vaccination, particularly against OSP. Younger children exhibited higher peak fold-change IgA responses to CTB than older children and adults across both infection and vaccine studies. Following vaccination, individuals from high-income countries showed higher IgA, IgG, and vibriocidal fold-change responses compared to those from lower-income settings, likely an artifact of baseline levels. Limited data from challenge studies revealed slower decay of IgG compared to IgA and IgM to OSP. This review enhances our understanding of longitudinal immune responses to *V. cholerae*, highlighting variability in antibody kinetics across populations, geographic regions, and study designs, and underscores the need for tailored epidemiological approaches to address bacterial diarrheal diseases on a global scale.

42 **Introduction**

43 Sero-epidemiology is an emerging field in which immunological markers from blood,
44 primarily antibodies, can be measured from population-based sampling and used to estimate
45 population-wide infection burden and immunity following vaccination or natural infection[1]. This
46 could be an important tool for monitoring disease prevalence and transmission, identifying gaps
47 in vaccine distribution or adherence, and strategizing public health interventions[2,3]. Despite its
48 growing importance, a critical and underexplored aspect of sero-epidemiology is the need for
49 data from studies of long-term kinetics and stability of antibody responses to inform
50 interpretations of single time-point measurements from individuals and populations and cross-
51 sectional sero-surveys.

52 Understanding longitudinal kinetics of immune responses, such as how long antibodies
53 remain detectable and the rate at which their levels decline, is particularly important for
54 addressing and managing global health threats like *Vibrio cholerae (V. cholerae),* the causative
55 agent of cholera. Cholera remains a significant public health challenge, responsible for up to 4
56 million cases and 150,000 deaths annually[4,5]. Cholera especially impacts those living in low- and
57 middle-income countries due to poor and inadequate health infrastructure, contaminated food
58 and water sources, and insufficient disease surveillance and monitoring systems[6].

59 Clinical manifestations of *V. cholerae* infection varies from asymptomatic to severe acute
60 watery diarrhea and vomiting, which can lead to severe dehydration and death due to
61 hypovolemic shock[7]. The number of medically-attended cases likely represents only a small
62 proportion of total infections, and sero-surveillance, while not measuring clinical disease
63 directly, offers a potential avenue for more accurate burden estimates[8]. While *V. cholerae* has
64 been a target for vaccine development as an intervention for global prevention and control[9],

vaccine efficacy is lower in young children compared to older persons, and antibody kinetics of young children may differ from those of adults. Sero-surveillance is an emerging method for assessment of cholera burden, but various questions remain, including whether antibody kinetics from one region, such as hyperendemic countries in Asia, could be generalizable to other regions, such as non-endemic countries, or endemic countries with infrequent outbreaks. Further, gathering data on long-term antibody persistence, or lack thereof, following *V. cholerae* exposure can inform public health efforts in both endemic and non-endemic settings.

This systematic review aims to survey and synthesize existing literature on global long-term antibody kinetics in humans following exposure to *V. cholerae*, with the goal of informing future research and public health strategies.

Methodology

Overview

We conducted a systematic review to analyze existing literature that report on longitudinal antibody response trajectories in humans after exposure to *Vibrio cholerae* through natural infection, vaccination, or controlled human challenge studies. Our methodology for this review was guided by the established systematic review framework developed by Khan and colleagues[10], providing a structured approach for mapping key concepts and gaps in literature.

We conducted this review in four key stages: 1) identifying relevant studies through a comprehensive search of databases, 2) screening and selecting studies for full-text review based on specific inclusion and exclusion criteria, 3) extracting relevant data from the included studies, and 4) collating, summarizing, and reporting the findings to highlight trends, patterns, knowledge gaps, and areas for future investigation related to long-term antibody kinetics.

Search Strategy

We conducted a systematic literature search using the PubMed and Embase databases to identify relevant articles. Our search strategy included phrases created using specific key words (**Table 1**). We used this strategy to identify articles from the earliest available time up to and including April 2025.

Table 1. Key terms and search phrases

Key Terms	
Line Number	**Term**
1	Cholera
2	Vibrio cholerae
4	Antibody
5	Human
Phrases using Key Terms	
[“2” OR 1] AND 4	
[“2” OR 1] AND 4 AND MeSH Terms[5]	

A total of 4,346 articles were identified and exported to Covidence online software where duplicates were removed.

Selection Criteria, Data Management, and Extraction

We used the Covidence online platform for screening, full text review, and data extraction. After duplicates were removed, 2,179 articles were available for title and abstract screening. We reviewed articles based on specific inclusion and exclusion criteria (**Table 2**).

Table 2. Inclusion and Exclusion Criteria

Study Characteristics	Inclusion Criteria	Exclusion Criteria
Study Design	Randomized and non-randomized Case only or case-control Acute and convalescent Pre-vaccine/post-vaccine Pre-challenge/post-challenge Point source outbreak with longitudinal follow up	Descriptive report or case-report without longitudinal follow-up Prevalence, diagnostic, prognostic, or comparison study Trial protocol Only in vitro measurement

Publication	Peer reviewed journal Published in English Abstract and full-text available	Any academic dissertation Conference proceedings, abstract, or poster Any pre-print
Pathogen	*Vibrio cholerae O1/O139*	Any other pathogen
Participants	Humans of all ages	Non-human studies
Interventions	Natural Infection Vaccine Trial Challenge Event	Any other type of exposure or unable to determine exposure event
Outcome Measures	Longitudinal antibody and/or vibriocidal titers (follow-up ≥ 28 days post onset of symptoms, final vaccine dose, or challenge event)	Antibody and vibriocidal titers not reported and/or no longitudinal follow-up

Two independent reviewers (MSB & ST or ST & AM) completed title and abstract screening using the inclusion criteria to ensure relevant studies were included for full-text review. We resolved any differences or discrepancies in inclusion/exclusion decisions between the two reviewers with discussion and consensus. Next, one independent reviewer (CC or AM) completed full-text reviews of included studies using the same inclusion and exclusion criteria (**Table 2**). Included studies from full-text reviews were then moved into the data extraction step. To ensure extraction of relevant data and to streamline the process, a data extraction template was created by AM within the Covidence platform. The extraction template was used by two independent reviewers (AM & KJ or AM & TH) to gather and consolidate relevant data including: study design, country, country income status (low-income, lower-middle-income, upper-middle-income, and high-income), and study type (infection, vaccine, challenge). Income status was determined based on the most recent classifications by the World Bank. Population specific data that was extracted included: inclusion and exclusion criteria, group differences, number of subjects, and population age (adult or pediatric). Finally, for each outcome measure,

we extracted antibody titers at baseline, peak, and end of study, and seroconversion information as available.

Analysis

Extracted data were imported into R for analysis. Population sample sizes corresponding to each extracted value were used to calculate weighted means and associated confidence intervals. Because of the variability in measurement scales and units across studies, analyses focused on the fold change in the titer relative to baseline values. Fold change was defined as the ratio of the titer at each timepoint to the baseline titer. As these data were heavily right-skewed, weighted means and confidence intervals were estimated using nonparametric bootstrapping with 5000 iterations.

Results

Study Identification

We reviewed 2,179 abstracts published prior to and including April 2025 (**Figure 1**). Of those, 166 were selected for full-text review, and data from 51 studies were extracted and analyzed. Included studies were published between 1980 and 2024.



Figure 1. Flow diagram illustrating the selection of studies included in the systematic review

A total of 4,346 records were identified through database searches (PubMed and Embase). After removal of 2,167 duplicates, 2,179 records underwent title and abstract screening by two independent reviewers, resulting in the exclusion of 2,013 records. Full-text review was conducted for 166 articles, of which 115 were excluded. Data extraction was completed for the remaining 51 studies by two independent reviewers. The final dataset included 51 studies: 16 natural infection studies, 38 vaccine studies, and 6 challenge studies.

Figure 2. Sample collection timelines and vaccine dosing schedules across included studies

Each horizontal line represents the timeline for a study (or study group), with blue circles indicating specimen collection timepoints and pink crosses indicating vaccine dosing events (vaccine studies only). Studies are grouped by study type (Challenge, Infection, Vaccine). Multiple rows for a single study denote different dosing or collection groups within that study. The x-axis displays standardized timepoints from baseline through later follow-up (e.g., day 7, day 14, month 3, year 1, etc.). Grey horizontal lines provide a visual guide to the duration and structure of each study's collection schedule.

146 The studies from which data were extracted were categorized into three types of pathogen
147 exposure, 1) natural infection, 2) vaccination, and 3) challenge strain (**Supplementary Table 1**).
148 The primary assay used throughout included studies was an enzyme-linked immunosorbent assay
149 (ELISA). Several studies also used vibriocidal assays. These assays were used to measure
150 immunoglobulin antibody levels (i.e. IgG, IgA, and IgM) to various antigens (e.g. LPS, CTB,
151 OSP) as well as vibriocidal responses in human serum and plasma.

152 Antigen type significantly influenced peak antibody responses across study types (**Table**
153 **3**). Natural infection studies showed significantly higher fold increases in IgG, IgA, and IgM
154 titers to O-Specific Polysaccharide (OSP) compared to vaccine and challenge studies (IgG: p =
155 0.0019; IgA: p=0.0004; IgM: p = 0.0013).

156 **Table 3. Weighted Peak Titer Comparisons Across Antigens by Isotype and Study Type**

Antigen	N_{eff}[a]	Peak Titer - Fold Change from Baseline [Weighted Mean (95% CI)]
IgG		
Natural Infection Studies		
O-Specific Polysaccharide (OSP)	3.6	5.7 (3.4 - 8.3)
Lipopolysaccharide (LPS)	3.6	2.8 (2.2 - 3.7)
Cholera Toxin B Subunit (CTB)	3.3	4.0 (3.5 - 4.6)
Cholera Toxin (CT)	1.0	12.5
Sialidase	1.0	3.6
Vaccine Studies		
O-Specific Polysaccharide (OSP)	8.6	1.7 (1.3 – 2.4)
Lipopolysaccharide (LPS)	7.9	2.3 (1.8 - 2.8)
Cholera Toxin B Subunit (CTB)	11.6	5.6 (3.8 - 8.2)
Cholera Toxin (CT)	5.7	8.9 (5.5 - 11.3)
Challenge Studies		
O-Specific Polysaccharide (OSP)	3.9	2.0 (1.2 - 3.2)
Cholera Toxin B Subunit (CTB)	2.4	6.8 (6.2 - 8.3)
Cholera Toxin (CT)	1.0	1.5
Toxin co-regulated pilus A (TcPA)	1.9	1.6 (1.5 - 1.8)
IgA		
Natural Infection Studies		
O-Specific Polysaccharide (OSP)	3.6	13.2 (6.2 - 18.6)

Lipopolysaccharide (LPS)	3.6	8.3 (3.1 - 16.2)
Cholera Toxin B Subunit (CTB)	3.6	8.0 (5.1 - 13.3)
Sialidase	2.0	1.9 (1.1 - 2.7)
Vaccine Studies		
O-Specific Polysaccharide (OSP)	8.6	2.8 (2.0 - 3.9)
Lipopolysaccharide (LPS)	7.9	3.7 (3.1 - 4.1)
Cholera Toxin B Subunit (CTB)	10.4	11.4 (7.1 - 16.7)
Cholera Toxin (CT)	4.4	14.1 (8.7 - 22.1)
Challenge Studies		
O-Specific Polysaccharide (OSP)	3.9	2.9 (1.6 - 4.8)
Toxin co-regulated pilus A (TcPA)	1.9	1.3 (1.2 - 1.5)
IgM		
Natural Infection Studies		
O-Specific Polysaccharide (OSP)	3.6	6.4 (3.5 - 9.6)
Lipopolysaccharide (LPS)	1.9	3.0 (2.1 - 5.3)
Cholera Toxin B Subunit (CTB)	1.1	1.1 (1.0 - 1.1)
Vaccine Studies		
O-Specific Polysaccharide (OSP)	8.6	1.7 (1.4 - 2.1)
Lipopolysaccharide (LPS)	1.6	1.8 (0.95 - 2.5)
Cholera Toxin B Subunit (CTB)	2.6	1.01 (1.0 - 1.04)
Challenge Studies		
O-Specific Polysaccharide (OSP)	3.9	2.3 (1.7 - 2.9)
Vibriocidal		
Natural Infection Studies	6.4	85.5 (37.5 - 176.2)
Vaccine Studies	6.5	110.8 (66.4 - 133.8)
Challenge Studies	1.9	8.8 (2.3 - 16.3)

[a] Effective Sample Size – results are weighted based on population sample size

[b] A one-way weighted ANOVA was performed for each variable with 3 or more groupings and a two-sample t-test was performed for each variable with only 2 groupings to determine if the average fold change from baseline in peak titers differs across groups

*Significant $p<0.05$



Figure 3. Weighted mean peak titers, fold change from baseline

Peak immune responses were identified as the highest fold change in antibody titer from baseline following symptom onset or vaccination. The figure displays weighted (based on sample size) mean peak titers for each antigen, stratified by study type and antibody isotype. Individual data points are overlaid with reduced transparency to illustrate the underlying distribution.

Natural Infection Studies

Among studies that involved natural cholera infection (*n*=16), antibody titers peaked between 7- and 30-days following onset of symptoms with majority of titers peaking at day 7. All studies involving natural infection were conducted in Bangladesh.

176 IgA responses varied by age group, with children aged 0–5 years exhibiting higher peak
177 fold increases compared to older children (5–18 years) and adults (**Supplementary Table 1**).
178 This age-related difference was also antigen-dependent with peak fold-change IgA responses to
179 cholera toxin B subunit (CTB) significantly more elevated in children aged 0–5 years compared
180 to older children and adults (**Supplementary Table 1**; $p = 0.0441$).
181 Longevity of antibody responses appeared to be influenced by isotype, with IgG having
182 more gradual declines than IgA following peak response. At 6 months after natural infection
183 (latest time point available for studies that included children), children had similar fold change
184 from baseline titers as that of adult populations (**Figure 4b**).
185



Figure 4. Longitudinal antibody responses in natural infection studies

Longitudinal fold-change antibody responses from eligible natural infection studies are shown and stratified by isotype (IgA, IgG, IgM). **A.** Overall longitudinal trends. **B.** Age-stratified longitudinal trends. Each point represents an individual observation, with point size proportional to the underlying sample size; transparency is applied to improve visualization of overlapping data. The dark solid line denotes the weighted mean response, and the shaded region indicates the 95% confidence interval across the 365 days following symptom onset.

194 ***Vaccine Studies***

195 Vaccination studies (*n*=38) were from 14 countries; Sweden (5 studies), Austria (1
196 study), United States (13 studies), Bangladesh (9 studies), Haiti (1 study), Columbia (1 study),
197 India (1 study), Switzerland (1 study), Thailand (3 studies), Pakistan (1 study), Gabon (1 study),
198 Australia (1 study), Cameroon (1 study), and Zambia (1 study), with some overlap. Vaccines
199 included Dukoral, Shanchol, and Peru-15. Studies involved single (*n*=19), two (*n*=16), and three
200 (*n*=7) vaccine doses.

201 Participants from high-income countries exhibited higher fold increases in peak
202 vibriocidal antibody titers compared to those from upper-middle, lower-middle, and low-income
203 countries (**Supplementary Table 2**). Additionally, peak fold increases in IgG and IgA responses
204 were also significantly higher in high-income countries compared to lower-middle income
205 countries (**Supplementary Table 2**). Peak fold increases in vibriocidal antibody responses were
206 highest among children aged 5–18 years compared to adults (**Supplementary Table 1**; $p <$
207 0.001). Longitudinally, antibody kinetics were highly variable overall and across population age
208 and country income group (**Supplementary Figure 1**).

209
210
211 ***Human Challenge Studies***

212 Limited data was extracted from studies that involved exposure to *V. cholerae* through a
213 challenge strain (*n*=6). Peak antibody titers occurred at 10, 14, and 28 days following the
214 challenge. All human challenge models were conducted in adult populations in the United States.
215 Longitudinal trends for challenge studies show that IgG peaks later than IgA and IgM (**Figure**
216 **5**).



Figure 5. Longitudinal antibody responses in challenge studies

Longitudinal fold-change antibody responses from challenge studies meeting inclusion criteria are shown and stratified by isotype (IgA, IgG, IgM). Each point represents an individual observation, with point size proportional to the contributing sample size; transparency is applied to enhance visualization of overlapping data. The dark solid line depicts the weighted mean response, and the shaded region represents the 95% confidence interval across the 182 days following the challenge event.

Discussion

Serological surveillance (i.e. sero-surveillance) serves as a promising yet underutilized tool for estimating disease burden particularly for pathogens like *Vibrio cholerae*[11,12]. This systematic review synthesizes findings from 51 studies to characterize longitudinal antibody kinetics following natural cholera infection, vaccination, or experimental challenge. By examining how antibody responses vary across intervention type, age group, and country income level, this review provides insights that can improve the interpretation of cross-sectional sero-surveys and inform public health strategies.

232 Our analysis reveals notable age-related differences in immune responses, particularly for
233 IgA antibodies. Children under 5 years of age exhibited significantly higher peak IgA responses
234 to the CTB antigen following natural infection but not vaccination compared to older children
235 aged 5-18 years and adults, possibly due to lower baseline levels. Another possible contributing
236 factor may be the immunological cross-reactivity between CTB and the heat-labile enterotoxin B
237 subunit (LTB) of enterotoxigenic *Escherichia coli* (ETEC), which share structural and antigenic
238 similarities[13]. A recent study similarly identified this trend, reporting substantial increases in IgA
239 and IgG responses to CTB after infection but not vaccination[14]. Interestingly, older children
240 demonstrated significantly higher fold changes in vibriocidal responses following vaccination
241 compared to adults. Importantly, these age-related differences in antibody kinetics suggest that
242 the age structure of a population must be considered when designing and interpreting
243 serosurveys.

244 Antibody responses following natural cholera infection were consistently stronger than
245 those elicited by vaccination, particularly for IgG, IgA, and IgM responses to the OSP antigen.
246 This finding is consistent with prior studies[14], underscoring the need to further investigate these
247 differences to reduce sero-incidence misclassification and inform other public health
248 interventions. Further, the persistence of antibody responses varied by isotype in both natural
249 infection and vaccine studies. As expected, IgG responses showed slower decay than IgA,
250 reflecting its longer half-life as a result of recycling through neonatal Fc receptor (FcRn)
251 binding[15]. Vaccine-induced antibody peaks were more variable than those following natural
252 infection, likely due to differences in vaccine formulation, dosing schedules, and administration
253 routes. These factors complicate interpretation of sero-epidemiologic findings and point to the
254 need for standardized methodologies in vaccine trials.

255 Participants from high-income countries exhibited significantly higher peak fold-changes
256 in IgG, IgA, and vibriocidal responses following vaccination compared to those from lower-
257 income settings. This disparity may reflect differences in baseline health status, exposure history,
258 gut microbiome composition, and nutritional factors[16–18]. These findings also emphasize the
259 importance of considering contextual factors when interpreting vaccine performance across
260 different populations.

261 The findings from this systematic review have several important implications for public
262 health and future immunological investigations. First, there is a clear need for standardized
263 protocols in measuring antibody responses[19], including specific antigen targets and time points
264 for sampling (**Figure 2**). Second, summarizing longitudinal antibody data can enhance our
265 interpretation of cross-sectional sero-surveys by providing critical context on seroprevalence and
266 exposure history for specific populations. This data can help distinguish recent from past
267 exposures and refine population-level disease burden and immunity estimates[19,20]. Finally, the
268 results of this study can inform sero-epidemiological studies. By characterizing antibody kinetics
269 across age groups, interventions, and geographic settings, the results fill a methodological gap in
270 sero-epidemiology to support the development of more accurate and precise cholera estimation
271 and transmission models.

272 While this review is comprehensive, there are several limitations to consider. First, some
273 studies, primarily ones published before 2000, utilized figures for presenting antibody titers and
274 concentrations rather than tables. The independent reviewers who performed data extraction
275 therefore made estimations and calculations based on information presented in the main text and
276 figure captions. To reduce subjective bias, these extractions were compared and refined based on
277 values derived with the online AI application, PlotDigitizer. Second, geographic representation

was unevenly distributed, with natural infection studies exclusively from Bangladesh and challenge studies only from the United States. Further, challenge studies were only conducted in adult populations, limiting our ability to make comparisons across age groups.

Conclusion

This review underscores the value of sero-surveillance in understanding cholera disease burden across populations, geographic regions, and interventions. By synthesizing global data on long term antibody kinetics in humans, this review provides a foundation for informing the design of future sero-epidemiological studies.

Funding

This work was supported by the National Institutes of Health (R01AI135115) and the Dr Thomas D. Rees and Natalie B. Rees Presidential Endowed Chair in Global Medicine (to DTL)

References

1. Evans AS. Surveillance and Seroepidemiology. In: Evans AS, editor. Viral Infections of Humans: Epidemiology and Control [Internet]. Boston, MA: Springer US; 1984 [cited 2025 June 6]. p. 43–64. Available from: https://doi.org/10.1007/978-1-4684-4727-9_2

2. Arnold BF, Scobie HM, Priest JW, Lammie PJ. Integrated Serologic Surveillance of Population Immunity and Disease Transmission. Emerg Infect Dis. 2018 July;24(7):1188–94.

3. Wilson SE, Deeks SL, Hatchette TF, Crowcroft NS. The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases. CMAJ. 2012 Jan 10;184(1):E70–6.

4. Cholera [Internet]. [cited 2025 June 6]. Available from: https://www.who.int/health-topics/cholera

5. Awofeso N, Aldbak K. Cholera, Migration, and Global Health – A Critical Review. International Journal of Travel Medicine and Global Health. 2018 Sept 1;6(3):92–9.

6. Asantewaa AA, Odoom A, Owusu-Okyere G, Donkor ES. Cholera Outbreaks in Low- and Middle-Income Countries in the Last Decade: A Systematic Review and Meta-Analysis. Microorganisms. 2024 Dec;12(12):2504.

7. Finkelstein RA. Cholera, Vibrio cholerae O1 and O139, and Other Pathogenic Vibrios. In: Baron S, editor. Medical Microbiology [Internet]. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996 [cited 2025 June 10]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK8407/

8. Azman AS, Lauer SA, Bhuiyan TR, Luquero FJ, Leung DT, Hegde ST, et al. Vibrio cholerae O1 transmission in Bangladesh: insights from a nationally representative serosurvey. Lancet Microbe. 2020 Dec;1(8):e336–43.

9. O'Ryan M, Vidal ,Roberto, del Canto ,Felipe, Salazar ,Juan Carlos, and Montero D. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Human Vaccines & Immunotherapeutics. 2015 Mar 4;11(3):584–600.

10. Khan KS, Kunz R, Kleijnen J, Antes G. Five Steps to Conducting a Systematic Review. J R Soc Med. 2003 Mar 1;96(3):118–21.

11. Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Trop Med Int Health. 2016 Sept;21(9):1086–98.

12. Jiles R, Klevens M, Hughes E. Surveillance and Seroepidemiology. Viral Infections of Humans. 2014 Feb 27;63–79.

13. Holmgren J, Svennerholm AM. Immunological cross-reactivity betweenEscherichia coli heat-labile enterotoxin and cholera toxin A and B subunits. Current Microbiology. 1979 Jan 1;2(1):55–8.

14. Jones FK, Bhuiyan TR, Slater DM, Ternier R, Hutt Vater KR, Khan AI, et al. Expanding cholera serosurveillance to vaccinated populations. medRxiv. 2025 Mar 11;2025.03.09.25323598.

15. Zakrzewicz A, Vanderheyden K, Galaly Y, Feldhoff S, Sips M, Brinkhaus M, et al. Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes. Front Immunol. 2024 Oct 10;15:1473637.

16. Desai SN, Cravioto A, Sur D, Kanungo S. Maximizing protection from use of oral cholera vaccines in developing country settings. Hum Vaccin Immunother. 2014 June 1;10(6):1457–65.

17. Parker EP, Ramani S, Lopman BA, Church JA, Iturriza-Gómara M, Prendergast AJ, et al. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol. 2018 Jan;13(1):97–118.

18. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010 Oct 4;8(1):129.

19. Hay JA, Routledge I, Takahashi S. Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data. Epidemics. 2024 Dec 1;49:100806.

20. Davis KL, Nieznanski C, Maisha FM, Brintz BJ, Clutter CH, Alam MT, et al. Long-term Kinetics of Vibriocidal Antibody Responses After Vibrio cholerae Infection in the Democratic Republic of Congo. J Infect Dis. 2025 July 22;jiaf382.

Included Studies in Systematic Review

1. Bergquist C, Johansson EL, Lagergård T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun. 1997 Jul;65(7):2676–84.

2. Cryz SJ, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun. 1995 Apr;63(4):1336–9.

3. Jertborn M, Svennerholm AM, Holmgren J. IgG and IgA subclass distribution of antitoxin antibody responses after oral cholera vaccination or cholera disease. Int Arch Allergy Appl Immunol. 1988;85(3):358–63.

4. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–42.

372 5. Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, et al. Peru-15, an
373 improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis. 1995
374 Oct;172(4):1126–9.

375 6. Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, et al. Estimating
376 cholera incidence with cross-sectional serology. Sci Transl Med. 2019 Feb
377 20;11(480):eaau6242.

378 7. Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, et al. Anti-O-
379 specific polysaccharide (OSP) immune responses following vaccination with oral cholera
380 vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-
381 type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis.
382 2018 Apr;12(4):e0006376.

383 8. Uddin T, Harris JB, Bhuiyan TR, Shirin T, Uddin MI, Khan AI, et al. Mucosal Immunologic
384 Responses in Cholera Patients in Bangladesh. Clin Vaccine Immunol CVI. 2011
385 Mar;18(3):506–12.

386 9. Uddin T, Aktar A, Xu P, Johnson RA, Rahman MA, Leung DT, et al. Immune responses to
387 O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult
388 Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in
389 patients with cholera. Am J Trop Med Hyg. 2014 May;90(5):873–81.

390 10. Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, et al. The Live
391 Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated
392 Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae. Clin Vaccine
393 Immunol CVI. 2017 Jan 5;24(1):e00470-16.

394 11. Leung DT, Rahman MA, Mohasin M, Patel SM, Aktar A, Khanam F, et al. Memory B cell
395 and other immune responses in children receiving two doses of an oral killed cholera vaccine
396 compared to responses following natural cholera infection in Bangladesh. Clin Vaccine
397 Immunol CVI. 2012 May;19(5):690–8.

398 12. Leung DT, Rahman MA, Mohasin M, Riyadh MA, Patel SM, Alam MM, et al. Comparison
399 of Memory B Cell, Antibody-Secreting Cell, and Plasma Antibody Responses in Young
400 Children, Older Children, and Adults with Infection Caused by Vibrio cholerae O1 El Tor
401 Ogawa in Bangladesh ▿ . Clin Vaccine Immunol CVI. 2011 Aug;18(8):1317–25.

402 13. Aktar A, Rahman MA, Afrin S, Faruk MO, Uddin T, Akter A, et al. O-Specific
403 Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and
404 Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Clin Vaccine Immunol CVI.
405 2016 May;23(5):427–35.

406 14. Weil AA, Chowdhury F, Khan AI, Leung DT, Uddin T, Begum YA, et al. Frequency of
407 reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an
408 episode of severe cholera in a highly endemic area in Bangladesh. Am J Trop Med Hyg.
409 2012 Nov;87(5):921–6.

410 15. Falkard B, Charles RC, Matias WR, Mayo-Smith LM, Jerome JG, Offord ES, et al. Bivalent
411 oral cholera vaccination induces a memory B cell response to the V. cholerae O1-
412 polysaccharide antigen in Haitian adults. PLoS Negl Trop Dis. 2019 Jan 31;13(1):e0007057.

413 16. Alam MM, Arifuzzaman M, Ahmad SM, Hosen MI, Rahman MA, Rashu R, et al. Study of
414 Avidity of Antigen-Specific Antibody as a Means of Understanding Development of Long-
415 Term Immunological Memory after Vibrio cholerae O1 Infection. Clin Vaccine Immunol
416 CVI. 2013 Jan;20(1):17–23.

417 17. Kendall EA, Tarique AA, Hossain A, Alam MM, Arifuzzaman M, Akhtar N, et al.
418 Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-
419 dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect
420 Immun. 2010 Jan;78(1):253–9.

421 18. Jayasekera CR, Harris JB, Bhuiyan S, Chowdhury F, Khan AI, Faruque ASG, et al. Cholera
422 Toxin–Specific Memory B Cell Responses Are Induced in Patients with Dehydrating
423 Diarrhea Caused by Vibrio cholerae O1. J Infect Dis. 2008 Oct 1;198(7):1055–61.

424 19. Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J. Antibody-producing
425 cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect
426 Immun. 1991 Mar;59(3):996–1001.

427 20. Akter A, Dash P, Aktar A, Jahan SR, Afrin S, Basher SR, et al. Induction of systemic,
428 mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific
429 polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell
430 cholera vaccine in Bangladesh. PLoS Negl Trop Dis. 2019 Aug;13(8):e0007634.

431 21. Leung DT, Bhuiyan TR, Nishat NS, Hoq MR, Aktar A, Rahman MA, et al. Circulating
432 mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and
433 associated with lipopolysaccharide antibody responses. PLoS Negl Trop Dis. 2014
434 Aug;8(8):e3076.

435 22. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of
436 infection-derived immunity to cholera. J Infect Dis. 1981 Jun;143(6):818–20.

437 23. Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castañeda E, Levine MM. Kinetics of
438 the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 1994
439 Aug;12(11):1000–3.

440 24. Tacket CO, Forrest B, Morona R, Attridge SR, LaBrooy J, Tall BD, et al. Safety,
441 immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera
442 hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun. 1990 Jun;58(6):1620–7.

443 25. Kanungo S, Lopez AL, Ali M, Manna B, Kim DR, Mahapatra T, et al. Vibriocidal antibody
444 responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata,
445 India. PloS One. 2014;9(5):e96499.

446 26. Viret JF, Favre D, Wegmüller B, Herzog C, Que JU, Cryz SJ, et al. Mucosal and systemic
447 immune responses in humans after primary and booster immunizations with orally
448 administered invasive and noninvasive live attenuated bacteria. Infect Immun. 1999
449 Jul;67(7):3680–5.

450 27. Sears SD, Richardson K, Young C, Parker CD, Levine MM. Evaluation of the human
451 immune response to outer membrane proteins of Vibrio cholerae. Infect Immun. 1984
452 May;44(2):439–44.

453 28. Migasena S, Pitisuttitham P, Prayurahong B, Suntharasamai P, Supanaranond W, Desakorn
454 V, et al. Preliminary assessment of the safety and immunogenicity of live oral cholera
455 vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun. 1989 Nov;57(11):3261–
456 4.

457 29. Mascart-Lemone F, Carlsson B, Jalil F, Hahn-Zoric M, Duchateau J, Hanson LA. Polymeric
458 and monomeric IgA response in serum and milk after parenteral cholera and oral typhoid
459 vaccination. Scand J Immunol. 1988 Oct;28(4):443–8.

460 30. Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, et al. Efficacy of
461 atovaquone/proguanil for malaria prophylaxis in children and its effect on the
462 immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis Off Publ Infect
463 Dis Soc Am. 2002 Nov 15;35(10):1147–54.

464 31. Chaicumpa W. Assessment of antibody responses and protective immunity in cholera
465 vaccinated subjects. 2018;

466 32. McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M. Safety and immunogenicity of
467 single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
468 Vaccine. 2018 Feb 1;36(6):833–40.

469 33. McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M. Age-related
470 immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a
471 randomized, controlled clinical trial. Vaccine. 2019 Mar 7;37(11):1389–97.

472 34. Bhuiyan MS, Hossain M, Sharmin S, Shirin A, Khanam F, Chowdhury F, et al. Assessment
473 of disease specific immune responses in enteric diseases using dried blood spot (DBS). PloS
474 One. 2019;14(6):e0218353.

475 35. Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of
476 Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population.
477 Clin Vaccine Immunol CVI. 2017 May 31;24(8):e00098-17, CVI.00098-17.

478 36. Alam MM, Leung DT, Akhtar M, Nazim M, Akter S, Uddin T, et al. Antibody Avidity in
479 Humoral Immune Responses in Bangladeshi Children and Adults following Administration
480 of an Oral Killed Cholera Vaccine. Clin Vaccine Immunol CVI. 2013 Oct;20(10):1541–8.

481 37. Jertborn M, Svennerholm AM, Holmgren J. Evaluation of different immunization schedules
482 for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine.
483 1993;11(10):1007–12.

484 38. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and
485 immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-
486 HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect
487 Immun. 1992 Oct;60(10):4430–2.

488 39. Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody
489 responses as indirect measures of intestinal immunity after oral cholera vaccination or
490 natural disease. J Clin Microbiol. 1986 Aug;24(2):203–9.

491 40. McCarty JM, Cassie D, Bedell L, Lock MD, Bennett S. Safety and Immunogenicity of Live
492 Oral Cholera Vaccine CVD 103-HgR in Children Aged 2-5 Years in the United States. Am J
493 Trop Med Hyg. 2020 Dec 14;104(3):861–5.

494 41. Adekunle O, Dretler A, Kauffman RC, Cho A, Rouphael N, Wrammert J. Longitudinal
495 analysis of human humoral responses after vaccination with a live attenuated V. cholerae
496 vaccine. PLoS Negl Trop Dis. 2021 Sep 3;15(9):e0009743.

497 42. Chowdhury F, Akter A, Bhuiyan TR, Biswas R, Firoj MG, Tauheed I, et al. Long-term
498 sialidase-specific immune responses after natural infection with cholera: Findings from a
499 longitudinal cohort study in Bangladesh. Front Immunol [Internet]. 2022 Dec 22 [cited 2025
500 Jul 3];13. Available from:
501 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1067737/full

502 43. Ateudjieu J, Sack DA, Nafack SS, Xiao S, Tchio-Nighie KH, Tchokomeni H, et al. An Age-
503 stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed
504 Second Dose in Cameroon. Am J Trop Med Hyg. 2022 Nov 14;107(5):974–83.

505 44. Ng Ombe H, Simuyandi M, Mwaba J, Luchen CC, Alabi P, Chilyabanyama ON, et al.
506 Immunogenicity and waning immunity from the oral cholera vaccine (ShancholTM) in
507 adults residing in Lukanga Swamps of Zambia. PloS One. 2022;17(1):e0262239.

508 45. Islam MT, Date K, Khan AI, Bhuiyan TR, Khan ZH, Ahmed S, et al. Co-administration of
509 Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A
510 Randomized Controlled Open Label Trial to Assess Interference. Clin Infect Dis Off Publ
511 Infect Dis Soc Am. 2023 Jan 13;76(2):263–70.

512 46. Kaisar MH, Bhuiyan MS, Akter A, Saleem D, Iyer AS, Dash P, et al. Vibrio cholerae
513 Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
514 mSphere. 2021 Apr 28;6(2):e01232-20.

515 47. McCarty JM, Cassie D, Bedell L, Lock MD, Bennett S. Long-Term Immunogenicity of Live
516 Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States.
517 Am J Trop Med Hyg. 2021 Apr 5;104(5):1758–60.

518 48. Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, et al. Safety
519 and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera
520 vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992 Jun;165(6):1042–8.

521 49. McCarty JM, Gierman EC, Bedell L, Lock MD, Bennett S. Safety and Immunogenicity of
522 Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
523 Am J Trop Med Hyg. 2020 Jan;102(1):48–57.

524 50. Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of
525 antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of
526 humans. Infect Immun. 1998 Jul;66(7):3390–6.

527 51. Dash P, Hakim A, Akter A, Banna HA, Kaisar MH, Aktar A, et al. Cholera toxin and O-
528 specific polysaccharide immune responses after oral cholera vaccination with Dukoral in
529 different age groups of Bangladeshi participants. mSphere. 2024 Mar 26;9(3):e0056523.

530

531